Oppenheimer Starts Amarin Corporation (AMRN) at Underperform, $7 PT

Oppenheimer analyst Leland Gershell initiates coverage on Amarin Corporation (NASDAQ: AMRN) with an Underperform rating and a price target of $7.00.

The analyst commented, "With a ~$7.3B EV, we believe AMRN’s valuation reflects expectations that, following an anticipated near-term label expansion of sole omega-3 product Vascepa: 1) sales will inflect and grow to $2B+ by 2023-24; and 2) operating margins will meaningfully improve. In contrast, we forecast sales growth to underwhelm and heavy selling costs to impede profitability. Furthermore, we believe that a ~12-month stream of late-stage competitor data starting next month will increasingly weigh on shares as these products, which we believe offer superior profiles, are factored into models. While some may regard AMRN as a probable M&A target, we see the likelihood of this outcome as only shrinking with time. We initiate coverage at Underperform with a $7 price target."

For an analyst ratings summary and ratings history on Amarin Corporation click here. For more ratings news on Amarin Corporation click here.

Shares of Amarin Corporation closed at $22.60 yesterday.

You May Also Be Interested In

• Roth/MKM Starts Dianthus Therapeutics (DNTH) at Buy
• Lucid Capital Markets Starts Hyperfine Inc. (HYPR) at Buy
• Itron (ITRI) PT Lowered to $105 at BNP Paribas Exane